Cargando…
One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi
In Malawi, 236 participants from the Advancing Cryptococcal Meningitis Treatment for Africa trial were followed for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericin B plus flucytosine was associated with the lowest 1 year mortality (27.5% [95% confid...
Autores principales: | Kanyama, Cecilia, Molloy, Síle F, Chan, Adrienne K, Lupiya, Duncan, Chawinga, Chimwemwe, Adams, Jack, Bright, Philip, Lalloo, David G, Heyderman, Robert S, Lortholary, Olivier, Jaffar, Shabbar, Loyse, Angela, van Oosterhout, Joep J, Hosseinipour, Mina C, Harrison, Thomas S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105249/ https://www.ncbi.nlm.nih.gov/pubmed/31155650 http://dx.doi.org/10.1093/cid/ciz454 |
Ejemplares similares
-
Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa
por: Chen, Tao, et al.
Publicado: (2019) -
Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
por: Shiri, Tinevimbo, et al.
Publicado: (2020) -
The treatment of a pregnant HIV positive patient with cryptococcal meningitis in Malawi. Case report and review of treatment options
por: Bright, Philip D., et al.
Publicado: (2017) -
Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy–Naïve and –Experienced Patients in Sub-Saharan Africa
por: Kalata, Newton, et al.
Publicado: (2021) -
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
por: Jarvis, Joseph N, et al.
Publicado: (2022)